On July 29, BEIGENE rose 3.33% in regular trading, trading at HK$200.0/share, with turnover of HK$54.25 million, reversing the prior session's over 3% decline.

On the news front, Nomura recently issued a research report raising BEIGENE's target price to HK$270.74, forecasting a 74% year-over-year increase in operating profit for the second quarter. Additionally, Huafu Securities initiated coverage with a \"Buy\" rating and a target price of HK$297.44, highlighting the company's entry into a new era of multi-curve growth. The company also recently announced an additional US$300 million investment to expand its U.S. manufacturing base and clinical R&D center. Coupled with positive progress from Brukinsa's MANGROVE Phase 3 clinical trial meeting its primary endpoint of progression-free survival, fundamental catalysts continue to emerge ahead of the August 5 earnings release.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)